Quantitative MRI and 3D-Printing for Monitoring Periprosthetic Joint Infection
Abstract
Joint replacements are becoming increasingly commonplace with over 130,000 joint arthroplasties being performed annually in Canada. Although joint replacement surgery is highly successful, implants do occasionally fail and need to be replaced via costly and difficult revision surgery. Periprosthetic joint infection (PJI) has recently become the leading reason for revision of both hip and knee replacements, which is unfortunate because PJI is difficult to diagnose and treat effectively; diagnosis is made particularly difficult by the lack of established non-invasive (imaging) means of evaluating PJI. This thesis aims to demonstrate that magnetic resonance imaging (MRI) has potential for diagnosing and monitoring PJI through advances in implant design and novel application of quantitative imaging.
The recent proliferation of metal 3D-printing has already inspired the clinical use of 3D-printed porous metal devices due to their favorable osseointegration and mechanical properties. This thesis explores an important MRI benefit to porous implants: their decreased effective magnetic susceptibility and proportional decrease in imaging artifacts. This is relevant to PJI because MRI is already well-established in diagnosing musculoskeletal infections, but metals cause image obscuring signal loss. This work shows that 3D-printed porous metal structures are likely to avoid this limitation, as their effective magnetic susceptibility is linearly proportional to porosity; if true, MRI will be able to diagnose PJI as easily as non-prosthetic joint infections.
This thesis describes a novel use for two important parameters measured by quantitative MRI: effective relaxation rate (R2*) and magnetic susceptibility (QSM; quantitative susceptibility mapping). This work seeks to address an important unmet need in PJI treatment – the ability to monitor drug release during localized antibiotic delivery – by exploiting these parameters’ proportionality to gadolinium concentration. This idea is centered around using gadolinium-based MRI contrast agents as a surrogate small-molecule that acts as a proxy for drugs to study diffusion-controlled release. An initial implementation of this concept showed promising results, including the ability to fit the data to a mathematical model of drug release. This shows the potential of MRI as a non-invasive means of monitoring localized antibiotic treatment of PJI post-revision.